Uterusun Mezenşimal Tümörlerinde Cd 117 Ekspresyonu

Amaç: Çalışmamızda uterusun çeşitli benign ve malign mezenşimal tümör gruplarında CD 117'nin immunohistokimyasal ekspresyonu, ile bu ekspresyonun tümör tipleri ve morfolojik özellikleri ile ilişkisini ve mezenşimal tümör/erin ayıncı tanı sındaki rolünü araştirmayı amaçladık. Gereç ve yöntem: Uterus kaynaklı 12 leiomyosarkoma (LMS); 8 düşük grade/i endometrial stromal sar ko ma ( DGESS), 4 atipik leiomyoma ( ALM), 31 sellüler leiomyoma (SLM) ile 9 klasik leiomyoma ( KLM) olgusunun parafin bloklarından yapılan kesitlere, immünohistokimyasal (İHK) yöntemle CD 117 boyaması uygulandı. Sonrasında %10 ve daha fazla orandaki türnöral hücrede immün reaktivite saptanması, pozitif olarak değerlendirildi. Boyanma yoğunluğu + 1 - +3 arasında; boyanma yaygınlığı ise fokal (%10-30), orta derecede (%30-60) ve diffüz (>%60) olarak derecelendirildi. istatiksel olarak Fisher'in kesin ki-kare testi ve Kolmogorov-Smirnov testleri kullanıldı. Bulgular: 12 LMS olgusunun ll i (%91.7), 8 ESS olgusunun 7 si (%87.5), 31 SLM'nın 27 si (%87); 4 ALM ve 9 KLM'nın tamamında (%100) pozitif boyanma izlendi. Kalan 6 olguda ekspresyon gözlenmedi. Boyanma dağılımı 19 olguda %30 un altında, 20 olguda %30-60, 19 olguda %60 ın üzerinde idi. Sonuç: Uterusun mezenşimal tümörlerinde farklı boyanma yoğunluğu ve dağılımı gösteren, yüksek oranda CD 117 ekspresyonu saptadık. İncelenen tümör tipleri ve morfolojik özellikleri arasında CD 117 ekspresyonu açısından anlamlı farklılık gözlemedik. İHK boyama yöntemleri ile CD 117 ekspresyonunun saptanması, bu proteinle ilişkili gen mutasyonunun varlığını tam olarak ifade etmemektedir. Bu çalışmaların moleküler patoloji yöntemiyle desteklenmesi ve CD 117 ekspresyonuna yol açan genetik mekanizmaların ortaya çıkanlması gerekmektedir.

Cd 117 Expressian in Uterin Mesenchymal Tumors

Aim:The aim of this study was to search the expressian of CD 117 in different groups of benign and malign uterin mesenchymal tumors and its relation with tumor types, morphologic properties and its role in differential diagnosis. Materials and Method:Histologic sections of paraffın blocks of 12 uterin leiomyosarkomas (LMS), 8 low grade endometrial stromal sarcomas (LGESS), 4 atypical leiomyomas (ALM), 31 eellu/ar leiomyomas (CLM) and 9 dassic leiomyomas were immunostained w ith CD 117 antibody. Individual tumars w ere considered positive if mor e than 1 O o/o of the ce lls comprising the neoplasm displayed immunreactive staining. Staining intensity was graded + 1 to +3 and distribution as focal (1 0-30% ), intermediate (30-60%) and diffuse (>60%). Results:Positive immunstaining was obtained in 11(91.7%) of the 12 LMS, 7 (87.5%) of the ESS, 27 (87%) of 31 CLM and all of the 4 ALM and 9 (100%) dassic leiomyoma. C-KlT expressian was not detected in 6 cas es. The distribution of immunohistochemical staining w as focal ( 30%) in 19 cases, intermediate (30-60%) in 20 cases and diffuse (>60%) in 19 cases. Conclusion:We determined high CD 117 expressian with different staining distribution and density in uterin mesenchymal tumors. We did not observe meaningful differences between tumor types and morphologic properties. Obtaining the immunohistochemical CD 117 expressian does not prove the genetic mutation related with this protein. These studies should be supported by malecular pathologic techniques and the genetic mechanisms that result with CD 117 expressian should be discovered.

PDF

___

1. Kurman RJ. B/austein' s Pathology of the Fema/e Genital Tract. In : Zaloudek C, Hendrickson MR (eds). Mesenchymal Tumors of the Uterus. 5th edition. New York : Springer-Verlag; 2002. 561-92.
2. Tavasoili FA , Devilee P, (eds). World Organization Classijication of Tumors Pathology and Genetics, Tumors of the Breası and Female GenituZ Organs. Lyon : IARC Press ; 2003. 233-42.
3. Ryan KJ, Berkowitz RS, Barbieri RL. Kistner' s Gynecology Principles and Practice. In: Muto MG, Friedman AJ ( eds). The U terine Corpus. 6 th edition. St. Louis, Missouri: Mos by; 1995. 159-61.
4. Nardal RR, Thoresen SO. Uterin Sarcomas in Norway. 1956-1992: Incidence, Survival and Mortality. Eur J Cancer 1997;33:907-11.
5. Leath CA, Straughn Jr. JM, et al. Immunohistochemical Evaluation of the c-kit Prota-oncagene in Sarcomas of the Uterus. J Reprod Med 2004; 49:71-5.
6. Salvalierra A, Tarrats A, Gomez C, Sustre MJ, Balana C. A case of c-kit positive high- grade sıramal endometrial sarcoma respondinf( to Imatinib Mesylate. Gynecol Oncol 2006;10I:545-7.
7. Wang L, Felix JC, Lee JL, et al. The prota-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Onco/2003;90:402-6.
8. Elmore LW, Damson K, Moore JR, Kornstein M, Burks R. Expressian of c-kit (CD 117) in Benign and Malignant Human Endometrial epitelium. Arch Pathal Lah Med 2001; 125:146-51.
9. Dorfrnan DM, Bui MM, Tubbs RR, Raymond R, et.al. CD17 Immunohistochemistry Tissue Microarray Survey for Quality Assurance and Interlaboratory Comparison. Arch Pathal Lah Med 2006; 130:779-82.
10. Mireskandari M, Shafaii AF, Kayser G, Kayser K. Lack of CD 117 and rare bcl-2 expressian in stomach cancer by immunuhistochemistry. An immunohistochemical study w ith review of the literature. Diagn Patho/2006; 16;1 ( 1 ):7.
11. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit Receptar and Stern Ce ll Factor in Gynecological Tumors. C lin Cancer Res 1994;54:3049-53.
12. Erdogan G, Bassorgan I, Pesterelli HE, Simsek T, Karaveli Seyda. C-kit protein expressian in uterine and o varian mesenchymal tumors. AP MIS 2007; ll5:204-9.
13. Mi etti ne n M, Lasota J. Gastrointestinal Sıromal Tumors: Review on Morphology, Malecular Pathology Prognosis and Dijferential Diagnosis. Are h Pathal Lah Med 2006;130:1466-78.
14. Raspollini MR,Amunni G, Vil/anucci A, et. al. c-Kit Expressian in Patients with U terine Leiomyosarcomas: A Potential Alternative Therapeutic Treatment. C lin Cancer Res 2004;1 0:3500-3.
15. Geller AM, Argenta P, Bradley W, et. al. Treatment and recurrence patterns in endometrial sıramal sarcomas and the relation to c-kit expression, Gynecol Onco/2004;95:632-6.
16. Nakayama M, Mitsuhashi T, Yoshihiko S, et. al. Immunohistochemical Evaluation of Expression in Sarcomas of the Gynecologic Region. Int J Gynecol Patho/2005;25:70-6.
17. Serrano C, Mackintosh C, Herrero D, et.al. Imatinib Is Not a Potential Alternative Treatment for Uterine Leiomyosarcoma. Clin Cancer Res 2005;ll (13):4970
18. Özçelik B, Akgün H, Serin Sİ, Başbağ M, Tayyar M. U terin Leiomyosarkoma/arda C-kit Pozitijliği İle Bcl-2 Artışı Arasındaki ilişki. Türk linekolojik Onkoloji Dergisi 2004;2:59-65.
19. Zajrakas M, Theodoridis TD, Zepiridis L, et al. KIT protein expressian in uterine sarcomas: an immunohistochemical study and review of the literatare. Eur J GyiUlecol Onco/2008;28:264-66.
20. Caudell JJ, Deavers MT, Stomotovitz MB, et. al. Imatinib Mesylate (Gleevec )-Targeted Kinuse s Are Expressed in U terine Sarcomas. Appl Immunohistae hem Mal Morpho/2005;31 :167-70.
21. Oliva E, Young RH, Amin BM, C/ement PB. An Immunohistochemical Analysis of Endometrial Sıramal and Smooth Masele Tumors of the Uterus. Am J Surg Patho/2002;26 (4):403-12.
22. Kle in WM, Kurınan RJ. Lack of c-kit Protein (CD117) in Mesenchymal Tumors of the Uterus and Ovary. Int J Gynecol Patho/2003;22:181-4.
23. Hornick JL, Fletcher CDM. Immunuhistochemical Staining for KIT (CD117) in Soft Tissue Sarcomas Is Very Limited in Distribution. Anat Patho/2002;117:188-93.
24. Lucas DR, al-Abbadi M, Tabaczka P, Hamre MR, Weaver DW, Mott MJ. c-Kit expressian in desmoid jibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J C lin Pathol. 2003 Mar;ll9(3):339-45.
25. Menezer J, Kravtsov V, Levy T, et. al. Expressian of c-kit in uterine carcinosarcoma. Gynecol Onco/2005;96:210-15.
26. Kalender ME, Sevine A, Yilmaz M, et. al. Detection of complete response to imatinib mesy/ate (Glivec!Gleevec) with 18F-FDG PET/CT for law grade endometrial sıramal sarcoma. Cancer Chemather Pharınacol. 2009;63:555-9.
27 Mitsuhashi T, Nakayama M, Sakurai S, et al. KIT-negative undijferentiated endometrial sarcoma with the amplijied epiderınal growth factor receptar gene showing a temporary response to imatinib mesy/ate. Ann Diagn Pathol. 2007; ll: 49-54.